Previous 10 | Next 10 |
Jounce Therapeutics ( JNCE ) Q2 results : Revenues: $17.4M (-10.3%). More news on: Jounce Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Jounce Therapeutics (NASDAQ: JNCE ): Q2 GAAP EPS of -$0.21 beats by $0.13 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with Celgene, received $50.0 million upfront - - Company to host conference call and webca...
Jounce Therapeutics ( JNCE ) established an updated deal with its partner Celgene ( CELG ). The new deal consists of a total amount of $530 million in potential payments, but it replaces an old deal established back in 2016 worth a potential $2.6 billion. Still, it is good to see tha...
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2019 financial result...
JNCE stock is moving up sharply following an update from Jounce Therapeutics (NASDAQ:JNCE) regarding its partnership with Celgene (NASDAQ:CELG). Investors Cheer the News Manufacturing of predictive biomarkers and immunotherapies is big business in the biotech space, and Jounce Therapeut...
Jounce Therapeutics (NASDAQ: JNCE ) +34% on revised Celgene collaboration . More news on: Jounce Therapeutics, Inc., Teradyne, Inc., Vislink Technologies, Inc., Stocks on the move, Read more ...
Gainers: JNCE +42.8% . SNAP +11.1% . EW +10.5% . MANH +9.6% . TXN +5.9% . More news on: Jounce Therapeutics, Inc., Snap Inc., Edwards Lifesciences Corporation, Stocks on the move, Read more ...
Jounce Therapeutics (NASDAQ: JNCE ) is up 41% after hours in reaction to its updated partnership with Celgene (NASDAQ: CELG ) under which the latter has in-licensed global rights to JTX-8064, an LILRB2 receptor-targeting monoclonal antibody. More news on: Jounce Therapeutics,...
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host conference call and webcast today at 5:00 p.m. ET - CAMBRIDGE, Mass., July ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...